Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Prostate. 2011 Feb 14;71(13):1441–1454. doi: 10.1002/pros.21361

Figure 7. Decrease in osteoblastic bone lesions with the systemic administration of TGFβ inhibitors in vivo.

Figure 7

(A) Bone volume to total tissue volume in tibia sections was quantified in control, TβRI-KI, and BGERII treatment groups using BIOQUANT analysis software. The line represents average value of bone volume to total tissue volume in the each group. Asterisk “*” indicates statistically significant difference among the control, TβRI-KI, and BGERII inhibitor treatment groups with one-way ANOVA followed with Tukey’s post-hoc test at P<0.01. (B) After the termination of experiment at seven weeks, bone sections from tibias without (injected with PBS) or with PacMetUT1 cell-formed tumors were stained for osteoclasts using TRAP assay. Representative TRAP stained bone sections showing presence of the stained osteoclasts are presented. (C) The TRAP-stained osteoclasts below the growth plate were counted in the sections of the tibias containing tumors from the three groups of mice treated with PBS, TβRI- KI, or BGERII. Data presented are mean ± SEM from all tibias with tumors in each group (8 from control, 5 from RI-KI group, and 9 from BGERII group). “ns” denotes no significant difference.